Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Emory University
University of California, San Diego
Emory University
Inhibrx Biosciences, Inc
Hookipa Biotech GmbH
Regeneron Pharmaceuticals
Intensity Therapeutics, Inc.
Vaccinex Inc.
National Cancer Institute (NCI)
Simcha IL-18, Inc.
Atara Biotherapeutics
UNICANCER
R-Pharm
Evopoint Biosciences Inc.
Icahn School of Medicine at Mount Sinai
Kineta Inc.
Fondazione del Piemonte per l'Oncologia
Genocea Biosciences, Inc.